Butterfly Network (NYSE:BFLY) and Precipio (NASDAQ:PRPO) Head-To-Head Contrast

Butterfly Network (NYSE:BFLYGet Free Report) and Precipio (NASDAQ:PRPOGet Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Volatility & Risk

Butterfly Network has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Butterfly Network and Precipio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Butterfly Network 1 2 3 0 2.33
Precipio 1 0 0 0 1.00

Butterfly Network presently has a consensus price target of $5.56, indicating a potential upside of 7.07%. Given Butterfly Network’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Butterfly Network is more favorable than Precipio.

Earnings and Valuation

This table compares Butterfly Network and Precipio”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Butterfly Network $97.61 million 13.55 -$77.06 million ($0.30) -17.32
Precipio $24.05 million 1.74 -$360,000.00 ($0.47) -49.70

Precipio has lower revenue, but higher earnings than Butterfly Network. Precipio is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Butterfly Network and Precipio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Butterfly Network -73.63% -34.41% -23.91%
Precipio -3.57% -6.73% -4.49%

Insider & Institutional Ownership

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 16.6% of Precipio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Butterfly Network beats Precipio on 10 of the 14 factors compared between the two stocks.

About Butterfly Network

(Get Free Report)

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

About Precipio

(Get Free Report)

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

Receive News & Ratings for Butterfly Network Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Butterfly Network and related companies with MarketBeat.com's FREE daily email newsletter.